How should I interpret prothrombin time (PT) and international normalized ratio (INR)?

How to Interpret Prothrombin Time (PT) and International Normalized Ratio (INR)

PT and INR are validated and clinically meaningful ONLY for monitoring vitamin K antagonist (VKA/warfarin) therapy—they should NOT be used to predict bleeding risk or guide plasma transfusion in patients not on VKAs. 1

Core Principles of Interpretation

For Patients on Warfarin/VKA Therapy

The INR was specifically designed and validated for this population:

• Therapeutic range typically 2.0-3.0 for most indications (atrial fibrillation, venous thromboembolism)
• Higher ranges (2.5-3.5) for mechanical heart valves
• The INR standardizes PT results across different laboratories by accounting for thromboplastin reagent variability using the International Sensitivity Index (ISI) 1, 2
• Formula: INR = (Patient PT/Mean Normal PT)^ISI 3, 4

Critical caveat: Even in warfarin patients, an initial INR rise can mask early procoagulant effects of warfarin, creating false reassurance about anticoagulation status 1

For Patients NOT on VKA Therapy

The INR has no validated clinical utility in non-VKA patients and should be interpreted with extreme caution:

• INR does NOT predict bleeding risk in liver disease, DIC, trauma, massive transfusion, or perioperative settings 1
• A systematic review found weak or no association between INR and bleeding in 78 of 79 studies in non-VKA patients (sensitivity <50%) 1
• Normal INR provides false reassurance—it has poor sensitivity for detecting bleeding disorders 1
• Elevated INR in non-VKA patients should NOT trigger plasma transfusion 1

Common Clinical Scenarios

Liver Disease

• The MELD score uses INR for disease severity scoring in transplant candidates
• However, INR does NOT predict bleeding risk in cirrhosis patients, either spontaneously or before procedures 1
• Liver-specific ISI calculations exist but are not routinely implemented 1

Perioperative/Preprocedural Setting

• INR elevation does not predict procedural bleeding risk in patients with or without cirrhosis 1
• Randomized trials show no reduction in bleeding when prophylactic plasma is given to correct INR in periprocedural, critically ill, or liver disease patients 1

Plasma Transfusion Decisions

Do NOT transfuse plasma based on mildly elevated INR alone:

• No high-quality evidence supports plasma transfusion for INR <2.0 in non-bleeding patients 1
• Plasma infusion does not meaningfully change INR values below 1.5 and only minimally impacts values below 2.0 1
• Requires massive volumes (20 mL/kg or 1.4 liters in 70 kg patient) for modest 20% factor repletion 1
• Exposes patients to volumetric and immunologic risks without proven benefit 1

Technical Considerations for Accurate INR

The INR calculation requires two critical components:

1. Mean Normal PT (MNPT): Laboratory-specific baseline value 1, 5
2. International Sensitivity Index (ISI): Reagent/instrument-specific calibration factor 1, 6, 5

Common pitfall: INR variability between laboratories remains problematic even with standardization, often due to inaccurate MNPT or ISI values 6, 5. Laboratories should verify these values rather than accepting manufacturer defaults.

Key Pitfalls to Avoid

• Do not use INR as a general coagulopathy screen—it was never designed or validated for this purpose 1
• Do not assume elevated INR = bleeding risk in non-VKA patients 1
• Avoid "ping-pong" dosing in warfarin patients by recognizing that random fluctuation can cause INR values outside therapeutic range without true clinical change 7
• Do not delay necessary procedures based solely on mildly elevated INR in non-VKA patients 1